Lyell Immunopharma, Inc. (LYEL)

Market Cap	222.26M -34.8%
Revenue (ttm)	27,000 -55.0%
Net Income	-248.48M
EPS	-11.82
Shares Out	24.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	129,452
Open	9.27
Previous Close	9.26
Day's Range	8.66 - 9.31
52-Week Range	8.66 - 45.00
Beta	-0.03
Analysts	Buy
Price Target	37.88 (+317.64%)
Est. Earnings	Nov 11, 2026

About LYEL

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy random...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 161
• Stock Exchange: Nasdaq
• Ticker Symbol: LYEL
• Website: https://www.lyell.com

Financial Performance

In 2025, Lyell Immunopharma's revenue was $36,000, a decrease of -40.98% compared to the previous year's $61,000. Losses were -$274.45 million, -19.98% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for LYEL stock is "Buy." The 12-month stock price target is $37.88, which is an increase of 317.64% from the latest price.

Price Target

$37.88

(317.64% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 6, 2026

Data Sources Report a data error